



2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Pegfilgrastim Agents

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with fields: Patient Name, Prescriber Name, Member Number, Date of Birth, Line of Business, Address, City, State ZIP, Primary Phone, Fax, Phone, Office Contact, NPI, State Lic ID, Specialty/facility name (if applicable).

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Form with fields: Drug Name, Strength, Directions / SIG.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Will pegfilgrastim be used as primary prophylaxis against febrile neutropenia?

Yes checkbox

No checkbox

Q2. Is the patient receiving myelosuppressive chemotherapy (attach documentation)?

Yes checkbox

No checkbox

Q3. Is the patient at increased risk for febrile neutropenia (attach documentation)?

Yes checkbox

No checkbox

Q4. Is the patient receiving dose-dense or high-dose chemotherapy (attach documentation)?

Yes checkbox

No checkbox

Q5. Will pegfilgrastim be used as secondary prophylaxis against febrile neutropenia?

Yes checkbox

No checkbox



2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Pegfilgrastim Agents

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name: Prescriber Name:

Q6. Is the patient receiving myelosuppressive chemotherapy with a history of febrile neutropenia during a previous course of chemotherapy for which primary prophylaxis was not received (attach documentation)?

Yes checkbox

No checkbox

Q7. For Ziextenzo Only: is there a diagnosis of hematopoietic subsyndrome of acute radiation syndrome with attached documentation of exposure to myelosuppressive doses of radiation?

Yes checkbox

No checkbox

Q8. Will the patient's complete blood count with differential including absolute neutrophil count (ANC) be monitored?

Yes checkbox

No checkbox

Q9. Additional Information:

Prescriber Signature

Date

2024 Prior Authorization Request